newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

  • Serina Therapeutics (NYSE: SER) appointed Farrell Simon, Pharm. D., to its Board of Directors effective immediately with immediate service on the Audit & Compensation Committees.
  • Dr. Simon currently serves as Chief Commercial Officer at Trevi Therapeutics, where he led commercial strategy, business development, & financings exceeding $400 million.
  • Prior to Trevi, Dr. Simon held senior leadership roles at Pfizer for a decade, including Biopharma Chief of Staff & global commercial positions.
  • CEO Steve Ledger stated Dr. Simon's experience in commercial strategy & investor engagement will aid advancing the SER-252 program & the POZ platform.
  • The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial evaluating subcutaneous SER-252 in adults with Parkinson's disease & motor fluctuations.
  • The SER-252-1b trial includes five single-ascending-dose cohorts (n=40) & up to three multiple-ascending-dose cohorts (n=48) across sites in the US, Australia, South Korea, & Taiwan.
  • SER-252 is an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation (CDS) to reduce levodopa-related motor complications.
  • Serina's proprietary POZ Platform utilizes poly(2-oxazoline) to control drug loading & release rates via subcutaneous injection for improved safety & efficacy.
  • Serina holds a non-exclusive license agreement with Pfizer Inc. to use POZ polymer technology in lipid nanoparticle (LNP) drug delivery formulations.
  • Serina plans to advance the POZ platform through out-licensing, co-development, & partnerships for various payloads & indications.
  • Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, developing drug candidates for neurological diseases.